T he insulin-like growth factor (IGF) pathway is a key mechanism for growth and survival in human cancers, including lung cancer. Because of the high expression of components of IGF signaling in lung cancer and early evidence of clinical activity in lung cancer, development of several novel agents targeting the IGF-1 receptor (IGF-1R) and the IGF pathway have included programs in lung cancer. 1, 2 Current agents in development are categorized as either anti-IGF-1R monoclonal antibodies (mAbs)

more »

... small molecule tyrosine kinase inhibitors (TKI), which as a class are earlier in clinical development. 3 The agents discussed at the meeting are summarized in Table 1 .